[go: up one dir, main page]

KR950701348A - 재조합 사람 락토페린 생산방법 - Google Patents

재조합 사람 락토페린 생산방법

Info

Publication number
KR950701348A
KR950701348A KR1019940703776A KR19940703776A KR950701348A KR 950701348 A KR950701348 A KR 950701348A KR 1019940703776 A KR1019940703776 A KR 1019940703776A KR 19940703776 A KR19940703776 A KR 19940703776A KR 950701348 A KR950701348 A KR 950701348A
Authority
KR
South Korea
Prior art keywords
plasmid
eukaryotic cell
lactophrine
glucoamylase
amylase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
KR1019940703776A
Other languages
English (en)
Other versions
KR0184693B1 (ko
Inventor
오로라 엠. 코네릴
데니스 알. 헤돈
버트 더블유. 오'말리
그레고리 에스. 메이
Original Assignee
사무엘 에스 크로커
베이롤 칼리지 오브 메드신
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 사무엘 에스 크로커, 베이롤 칼리지 오브 메드신 filed Critical 사무엘 에스 크로커
Publication of KR950701348A publication Critical patent/KR950701348A/ko
Priority to KR1019980707113A priority Critical patent/KR100221404B1/ko
Application granted granted Critical
Publication of KR0184693B1 publication Critical patent/KR0184693B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

본 발명은 신규한 플라스미드 형질전환된 진핵세포, 이 플라스미드와 진핵세포의 생성방법을 제공한다. 신규한 플라스미드는 사람 락토폐린 단백질의 cDNA를 포함한다. A. 오리자에서 사람 락토폐린 단백질의 생산방법이 제공된다.
따라서 본 발명은 재조합 사람 락토폐린 단백질의 생산을 위한 효과적이고 경제적인 수단을 제공한다.

Description

재조합 사람 락토페린 생산방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 아스피라질러스 오리자 발현 플라스미드 pAhlfg의 구조이다.
제3도는 형질전환체와 콘트롤 A07의 RNA분석을 설명한다.

Claims (21)

  1. 생물학적으로 활성이 있는 재조합 락토페린을 생산하는 방법에 있어서, 선택성 표식유전자, 프로모터, 전사종료서열과 링커(linker) 서열을 복합시키고; 플라스미드를 만들기 위해 서열을 클로닝시키고; 제한 효소로 플라스미드를 절단시키고; 제한효소 부위에 락토폐린 cDNA 코드를 삽입시키고; 그리고 락토폐린 cDNA를 발현시키는 플라스미드를 진핵세포에 형질도입시키는 단계로 구성된 것을 특징으로 하는 방법.
  2. 제1항에 있어서, 선택성 표식유전자는 pyr4, pyrG, andS, argB와 trpC에서 선택되는 것을 특징으로 하는 방법.
  3. 제1항에 있어서, 세포가 락토폐린을 발현시키는 것을 특징으로 하는 방법.
  4. 제2항의 방법에 따라 생성된 것을 특징으로 하는 락토폐린.
  5. 제1항에 있어서, 프로모터는 알코올 가수분해효소, argB, α-아밀라제, 글루코아밀라제와 benA에서 선택되는 것을 특징으로 하는 방법.
  6. 제1항에 있어서, 전사종료서열은 α-아밀라제, 글루코아밀라제, 알코올 가수분해효소 benA에서 선택되는 것을 특징으로 하는 방법.
  7. 제1항에 있어서, 링커서열은 α-아밀라제, 글루코아밀라제와 락토폐린에서 선택되는 것을 특징으로 하는 방법.
  8. 도면 6의 cDNA로 구성되고 진핵세포에서 cDNA를 발현시키는데 필요한 조절요소로 구성된 진핵세포에서 발현하기에 적합한 것을 특징으로 하는 플라스미드.
  9. pAhLFG플라스미드.
  10. 제8항에 따른 플라스미드를 포함하는 것을 특징으로 하는 진핵세포.
  11. 제10항에 있어서, 진핵세포는 곰팡이와 곤충세포에서 선택되는 것을 특징으로 하는 진핵세포.
  12. 제11항에 있어서, 곤충세포는 SF9인 것을 특징으로 하는 진핵세포.
  13. 제11항에 있어서, 곰팡이는 이스트인 것을 특징으로 하는 진핵세포.
  14. 제13항에 있어서, 이스트가 아스퍼질러스인 것을 특징으로 하는 진핵세포.
  15. 제14항에 있어서, 아스퍼질러스 균주는 A. 오리자(ortzae), A. 나이저(Niger), A. 니듈란(Nidulans0과 A. 오와모리(Awamori)에서 선택되는 것을 특징으로 하는 진핵세포.
  16. 재조합 플라스미드를 포함하는 형질전환체 진핵세포를 락토폐닌을 생산하는 공정에 있어서, 플라스미드는 락토폐린 단백질을 코드하는 폴리데옥시 리보뉴클레오티드를 가지는 플라스미드 벡터로 구성되고, 이는 적절한 염 양배지에서 락토폐린 단백질이 형성될때까지 배양하여 사람 락토폐린을 분리하는 단계로 구성된 것을 특징으로 하는 공정.
  17. (1)유전자 발현에서 조절역할을 하는 유전자 요소; (2)사람 락토폐린에 대한 cDNA코드; 그리고(3)적절한 전사와 해독개시와 종료서열로된 전사유닛을 가지는 것을 특징으로 하는 재조합 발현벡터.
  18. 제17항에 있어서, 유전자 요소가 프로모터인 것을 특징으로 하는 재조합 발현벡터.
  19. 제18항에 있어서, 프로모터는 알코올 분해효소, argB, α-아밀라제, 글루코아밀라제와 benA에서 선택되는 것을 특징으로 하는 재조합 발현벡터.
  20. 제17항에 있어서, 전사종료서열을 알코올 분해효소, argB, α-아밀라제, 글루코아밀라제와 benA에서 선택되는 것을 특징으로 하는 재조합 발현벡터.
  21. 제16항에 따라 생성된 것을 특징으로 하는 단백질.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019940703776A 1992-04-24 1993-04-16 재조합 사람 락토페린 생산방법 Expired - Lifetime KR0184693B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1019980707113A KR100221404B1 (en) 1992-04-24 1998-09-10 Production of recombinant human lactoferrin

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87330492A 1992-04-24 1992-04-24
US7/873,304 1992-04-24
PCT/US1993/003614 WO1993022348A1 (en) 1992-04-24 1993-04-16 Production of recombinant human lactoferrin

Publications (2)

Publication Number Publication Date
KR950701348A true KR950701348A (ko) 1995-03-23
KR0184693B1 KR0184693B1 (ko) 1999-04-01

Family

ID=25361366

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1019940703776A Expired - Lifetime KR0184693B1 (ko) 1992-04-24 1993-04-16 재조합 사람 락토페린 생산방법
KR1019980707113A Expired - Lifetime KR100221404B1 (en) 1992-04-24 1998-09-10 Production of recombinant human lactoferrin

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1019980707113A Expired - Lifetime KR100221404B1 (en) 1992-04-24 1998-09-10 Production of recombinant human lactoferrin

Country Status (18)

Country Link
US (1) US5571896A (ko)
EP (1) EP0644899B1 (ko)
JP (1) JP2824332B2 (ko)
KR (2) KR0184693B1 (ko)
CN (2) CN1047204C (ko)
AT (1) ATE177473T1 (ko)
AU (1) AU681583B2 (ko)
BR (1) BR9306289A (ko)
CA (1) CA2134094C (ko)
DE (1) DE69323879T2 (ko)
DK (1) DK0644899T3 (ko)
ES (1) ES2132232T3 (ko)
GR (1) GR3029942T3 (ko)
IL (1) IL105400A (ko)
NZ (1) NZ252844A (ko)
SG (1) SG47605A1 (ko)
WO (1) WO1993022348A1 (ko)
ZA (1) ZA932568B (ko)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL94183A (en) * 1989-05-05 2003-09-17 Baylor College Medicine cDNA SEQUENCE CODING FOR HUMAN LACTOFERRIN PROTEIN OR PORTION THEREOF AND LACTOFERRIN PROTEIN PRODUCED FROM SAID SEQUENCE
US5571697A (en) * 1989-05-05 1996-11-05 Baylor College Of Medicine Texas Medical Center Expression of processed recombinant lactoferrin and lactoferrin polypeptide fragments from a fusion product in Aspergillus
US5633076A (en) * 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US6066469A (en) * 1990-03-08 2000-05-23 Ferro Dynamics, Inc. Cloning, expression, and uses of human lactoferrin
JP3529423B2 (ja) * 1994-04-01 2004-05-24 森永乳業株式会社 抗菌性ペプチドの製造方法
FR2735983B1 (fr) 1995-06-29 1997-12-05 Centre Nat Rech Scient Peptide permettant de modifier l'activite du systeme immunitaire humain ou animal
DE19540233B4 (de) * 1995-10-19 2005-08-25 Schering Ag Sulfamat-Derivate von 1,3,5(10)-Estratrien-Derivaten, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
US6111081A (en) * 1996-05-31 2000-08-29 Baylor College Of Medicine Lactoferrin variants and uses thereof
EP1017407A2 (en) 1997-02-03 2000-07-12 Pharming Intellectual Property BV Useful properties of human lactoferrin and variants thereof
WO2000004132A1 (en) * 1998-07-15 2000-01-27 Samyang Genex Corporation Mass production method of lactoferrin polypeptide from yeast and useful microorganism thereof
JP3681982B2 (ja) 1998-07-15 2005-08-10 サムヤン ジェネックス コーポレイション 酵母からラクトフェリンポリペプチドを大量生産する方法及びそれに有用な微生物菌株
US6399570B1 (en) 1999-02-05 2002-06-04 Agennix, Inc. Antimicrobial/endotoxin neutralizing polypeptide
AU7042000A (en) * 1999-10-19 2001-05-14 Easy Bio System, Inc. Recombinant yeast strain for expressing human lactoferrin, n-lobe lactoferrin, c-lobe lactoferrin and process for preparation recombinant human lactoferrin, n-lobe lactoferrin, c-lobe lactoferrin using the same
US7417178B2 (en) * 2000-05-02 2008-08-26 Ventria Bioscience Expression of human milk proteins in transgenic plants
US7138150B2 (en) * 2000-05-02 2006-11-21 Ventria Bioscience Method of making an anti-infective composition for treating oral infections
US20080050503A1 (en) * 2000-05-02 2008-02-28 Ning Huang Expression of human milk proteins in transgenic plants
US20070031440A1 (en) * 2001-08-30 2007-02-08 Prior Christopher P Modified transferin-antibody fusion proteins
US20030226155A1 (en) * 2001-08-30 2003-12-04 Biorexis Pharmaceutical Corporation Modified transferrin-antibody fusion proteins
US7176278B2 (en) * 2001-08-30 2007-02-13 Biorexis Technology, Inc. Modified transferrin fusion proteins
US8129504B2 (en) 2001-08-30 2012-03-06 Biorexis Technology, Inc. Oral delivery of modified transferrin fusion proteins
MXPA04001804A (es) * 2001-08-30 2005-03-07 Biorexis Pharmaceutical Corp Proteinas de fusion de transferrina modificada.
WO2003057712A2 (en) * 2001-12-28 2003-07-17 Campina B.V. Humanized lactoferrin and uses thereof
PT1507554E (pt) * 2002-05-10 2011-11-21 Agennix Inc Lactoferrina no tratamento de neoplasmas malignos e outras doenças hiperproliferativas
AU2003233583A1 (en) * 2002-05-24 2003-12-12 Agennix Incorporated Oral lactoferrin in the treatment of respiratory disorders
US20060105387A1 (en) * 2002-08-30 2006-05-18 Prior Christopher P Transferrin fusion proteins libraries
DE60333306D1 (de) * 2002-08-30 2010-08-19 Biorexis Pharmaceutical Corp Modifizierte transferrin-fusionsproteine mit doppelten transferrin-amino- oder carboxy-terminalen domänen
DK1545587T3 (da) 2002-09-16 2011-05-09 Agennix Inc Lactoferrinsammensætninger og fremgangsmåder til behandling af diabetiske sår
JP4795021B2 (ja) * 2002-12-06 2011-10-19 エイジェニックス インコーポレイテッド 敗血症治療における経口用ラクトフェリン
AU2003296447A1 (en) * 2002-12-10 2004-06-30 Agennix Incorporated Lactoferrin as an agent in the prevention of organ transplant rejection and graft-versus-host-disease
US20070060512A1 (en) * 2003-03-04 2007-03-15 Homayoun Sadeghi Dipeptidyl-peptidase protected protein
KR100468596B1 (ko) * 2003-04-04 2005-01-27 (주) 디지탈바이오텍 메탄올자화효모인 피치아 패스토리스를 이용하여 인간락토페린을 생산하는 방법, 이 방법에 의해 제조된 인간락토페린 및 피치아 패스토리스 균주
US7379700B2 (en) * 2003-05-06 2008-05-27 Canon Kabushiki Kaisha Image reading apparatus with rotatable internal and external guides
WO2005046571A2 (en) * 2003-06-06 2005-05-26 Agennix Incorporated Lactoferrin as an adjuvant in cancer vaccines
US20040259770A1 (en) * 2003-06-19 2004-12-23 Rush University Medical Center Method for determining leukocyte activation
US20050075277A1 (en) * 2003-07-10 2005-04-07 Agennix Incorporated Use of lactoferrin in prophylaxis against infection and/or inflammation in immunosuppressed subjects
EP1663278A4 (en) * 2003-08-28 2009-07-29 Biorexis Pharmaceutical Corp EPO MIMETIC PEPTIDES AND FUSION PROTEINS
US20060205037A1 (en) * 2003-08-28 2006-09-14 Homayoun Sadeghi Modified transferrin fusion proteins
GB0329722D0 (en) 2003-12-23 2004-01-28 Delta Biotechnology Ltd Modified plasmid and use thereof
WO2005085287A1 (en) * 2004-03-03 2005-09-15 En-N-Tech, Inc. Treatments for contaminant reduction in lactoferrin preparations and lactoferrin-containing compositions
WO2006047744A2 (en) * 2004-10-26 2006-05-04 Agennix Incorporated Compositions of lactoferrin related peptides and uses thereof
EP2330200B1 (en) 2004-12-23 2017-04-05 Albumedix A/S Gene expression technique
WO2007150049A2 (en) 2006-06-22 2007-12-27 Agennix Incorporated Lactoferrin as a radioprotective agent
DK2046826T3 (da) * 2006-07-24 2011-10-24 Biorexis Pharmaceutical Corp Exendin-fusionsproteiner
NZ555163A (en) 2007-05-14 2010-05-28 Fonterra Co Operative Group Methods of immune or hematological enhancement, inhibiting tumour formation or growth, and treating or preventing cancer, cancer symptoms, or the symptoms of cancer treatments
ES2518290T3 (es) 2007-07-10 2014-11-04 Glanbia Nutritionals (Ireland) Limited Método de eliminación de endotoxinas de proteínas
WO2011104352A1 (en) 2010-02-25 2011-09-01 Agennix Ag Oral lactoferrin in the treatment of severe sepsis
JP6322576B2 (ja) * 2012-07-03 2018-05-09 花王株式会社 有用微生物および目的物質の製造方法
CA3118514A1 (en) * 2018-11-06 2020-05-14 Arhel Projektiranje In Inzeniring D.O.O. Method for manufacturing highly purified lactoferrin and lactoperoxidase from milk, colostrum and acid or sweet whey
KR200494603Y1 (ko) 2019-12-09 2021-11-12 한국청소년활동진흥원 타워형 구조를 이루는 기술 융합형 조립 교구

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4652639A (en) * 1982-05-06 1987-03-24 Amgen Manufacture and expression of structural genes
US4740461A (en) * 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US4935349A (en) * 1986-01-17 1990-06-19 Zymogenetics, Inc. Expression of higher eucaryotic genes in aspergillus
DK122686D0 (da) * 1986-03-17 1986-03-17 Novo Industri As Fremstilling af proteiner
WO1988005784A1 (en) * 1987-01-30 1988-08-11 The Board Of Trustees Of The Leland Stanford Junio Lymphocyte inhibition by hla peptides
DE3886221T3 (de) * 1987-09-04 2000-12-21 Novo Nordisk A/S, Bagsvaerd VERFAHREN ZUR HERSTELLUNG VON PROTEINPRODUKTEN IN -i(ASPERGILLUS) UND PROMOTOREN ZUR VERWENDUNG IN -i(ASPERGILLUS).
IL94183A (en) * 1989-05-05 2003-09-17 Baylor College Medicine cDNA SEQUENCE CODING FOR HUMAN LACTOFERRIN PROTEIN OR PORTION THEREOF AND LACTOFERRIN PROTEIN PRODUCED FROM SAID SEQUENCE
US5155037A (en) * 1989-08-04 1992-10-13 The Texas A&M University System Insect signal sequences useful to improve the efficiency of processing and secretion of foreign genes in insect systems
WO1991013982A1 (en) * 1990-03-08 1991-09-19 Ferrodynamics, Inc. Genetically engineered human lactoferrin
JP2818056B2 (ja) * 1990-09-07 1998-10-30 森永乳業株式会社 抗菌性ペプチドおよび抗菌剤

Also Published As

Publication number Publication date
DE69323879D1 (de) 1999-04-15
EP0644899A1 (en) 1995-03-29
ATE177473T1 (de) 1999-03-15
JPH08504561A (ja) 1996-05-21
CN1161382C (zh) 2004-08-11
KR100221404B1 (en) 1999-10-01
CA2134094C (en) 2004-01-06
WO1993022348A1 (en) 1993-11-11
DE69323879T2 (de) 1999-11-04
SG47605A1 (en) 1998-04-17
IL105400A0 (en) 1993-08-18
KR0184693B1 (ko) 1999-04-01
AU4289293A (en) 1993-11-29
CN1047204C (zh) 1999-12-08
CN1079780A (zh) 1993-12-22
EP0644899B1 (en) 1999-03-10
IL105400A (en) 2003-03-12
GR3029942T3 (en) 1999-07-30
HK1027360A1 (en) 2001-01-12
ES2132232T3 (es) 1999-08-16
AU681583B2 (en) 1997-09-04
EP0644899A4 (en) 1996-06-26
BR9306289A (pt) 1998-06-30
US5571896A (en) 1996-11-05
NZ252844A (en) 1996-05-28
DK0644899T3 (da) 1999-09-27
JP2824332B2 (ja) 1998-11-11
CA2134094A1 (en) 1993-11-11
CN1250055A (zh) 2000-04-12
ZA932568B (en) 1993-11-12

Similar Documents

Publication Publication Date Title
KR950701348A (ko) 재조합 사람 락토페린 생산방법
ES2150188T3 (es) Procedimiento para la preparacion de una proteina mediante un hongo transformado por integracion multicopia de un vector de expresion.
WO1996021022A3 (en) Production of gamma linolenic acid by a δ6-desaturase
KR970707283A (ko) 아스퍼질러스에서 융합 단백질로부터 프로세스된 락토페린과 락토페린 폴리펩티드 단편의 발현 방법(expression of processes recombinant lactoferrin and lactoferrin polypeptide fragments from a fusion product in aspergillus)
DE69532283T2 (de) EIN PILZ, IN DEM DAS areA-GEN VERÄNDERT IST, UND EIN areA-GEN AUS ASPERGILLUS ORYZAE
ATE78293T1 (de) Verfahren zur herstellung eines rekombinanten baculovirus-expressionsvektors.
CA2403842A1 (en) Increased production of secreted proteins by recombinant eukaryotic cells
DK1117808T3 (da) Transformaationssystem inden jfjor området filamentöse svampeværter: I chrysosporium
WO2003012071A3 (en) Nucleic acids of aspergillus fumigatus encoding industrial enzymes and methods of use
NZ333998A (en) Method for reducing expression variability of transgenes in plant cells using DNA constructs comprising insulator elements
ATE450605T1 (de) Phytase enzyme, dafür kodierende nukleinsäuren, und solche enthaltende vectoren und wirtszellen
CA2136618A1 (en) Expression of genes in transgenic plants
FI861696A0 (fi) Foerfarande foer isolering av fermentationsprodukter.
US4898823A (en) DNA sequence
GB9930019D0 (en) Improved protein expression strains
EP0837931A4 (en) PROCESS FOR THE EXPRESSION AND ISOLATION OF BIOLOGICALLY ACTIVE MOLECULES IN URINE
CA2229204A1 (en) Deubiquitinating enzymes that regulate cell growth
EP0363127A3 (en) Improvements in or relating to eukaryotic expression
EP0714445A1 (en) Glucoamylase promoter obtained from neurospora crassa and its use in the production of heterologous polypeptides
CA2037677A1 (en) Process for production of exogenous gene or its product in plant cells
CA2298106A1 (en) A recombinant expression vector of human parathyroid hormone
DK600386A (da) Proteinekspression
ATE295890T1 (de) Vektor zur expression von n-terminal verlängerten proteinen in hefezellen
EP0833898A1 (en) A process for producing trypsin (trypsinogen)
ATE202381T1 (de) Neue prosequenz zur sekretion heterologer proteine aus hefezellen

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 19941024

Patent event code: PA01051R01D

Comment text: International Patent Application

A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 19950412

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 19971222

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 19980608

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 19981012

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 19981221

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 19981221

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20011213

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20021204

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20031204

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20041210

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20051208

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 20061211

Start annual number: 9

End annual number: 9

PR1001 Payment of annual fee

Payment date: 20071207

Start annual number: 10

End annual number: 10

PR1001 Payment of annual fee

Payment date: 20081202

Start annual number: 11

End annual number: 11

PR1001 Payment of annual fee

Payment date: 20091210

Start annual number: 12

End annual number: 12

PR1001 Payment of annual fee

Payment date: 20101208

Start annual number: 13

End annual number: 13

PR1001 Payment of annual fee

Payment date: 20111206

Start annual number: 14

End annual number: 14

FPAY Annual fee payment

Payment date: 20121130

Year of fee payment: 15

PR1001 Payment of annual fee

Payment date: 20121130

Start annual number: 15

End annual number: 15

EXPY Expiration of term
PC1801 Expiration of term

Termination date: 20131022

Termination category: Expiration of duration